RxDoctor Payments Data

William Boysen, MD

Urology · Boston, MANPI 1912346503

Payments from drug & device makers

What this record shows

This record is dominated by grants: $50,000 of the $56,415 with a category attached, or 88.6%. Boston Scientific accounts for 91.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $51,227 and has fallen 98.6% since, to $723 in 2025. Among urology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,415in general payments, 2019–2025

Across 38 payments — averaging $1484.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$51K
  • Intuitive Surgical$4K
  • BD$419
  • Coloplast$205
  • AbbVie$177
  • Kerecis Limited$97
  • plus $84 from 1 others

What the payments were for

  • Grants$50,00089%
  • Travel & lodging$1,9553%
  • Food & beverage$1,4603%
  • Education$3,0005%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,415 in reported general payments places this provider in the 95th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$173,582
Medicare patients
382
Services billed
1,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron171$117,383
GemtesaVibegron23$17,739
Mirabegron ErMirabegron11$7,145
Trospium Chloride61$5,756
Methenamine Hippurate79$4,853
Tamsulosin Hcl240$4,666
Tolterodine Tartrate ErTolterodine Tartrate35$4,424
Finasteride170$2,313
Solifenacin Succinate38$1,938
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst39$728
Oxybutynin Chloride ErOxybutynin Chloride25$547
Alfuzosin Hcl ErAlfuzosin Hcl20$389
Oxybutynin Chloride12$373
Trimethoprim16$357
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$190

Paid to pharmacies, not to this prescriber.

Other urology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →